Search results for: Maria Lowe

Antibacterials: Roundtable Addresses the Critical Issues

10 November 2011

…The current situation is due primarily to two causes: inappropriate use in humans and animals, and the decline in the development of new antibacterials, largely because of lower returns on…

New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?

14 June 2012

…since 2000 and have remained at a level lower than during the 1990s.  He identifies two reasons for this.  First, development times (patent filing to market launch) have increased markedly. …

New Study of Time Lags in Translating Medical Research into Practice

30 November 2012

…made clear, the time that elapses between discoveries in medical research and adoption in practice is important. Longer time lags mean a lower rate of return on the research investment,…

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement

17 February 2015

…undermines the relationship between drug prices and per capita income Generics are priced roughly 30% lower than originators on average, but the variance is large, and this could reflect poorer…

Newly Published Analysis: Dementia: the R&D Landscape

16 November 2015

…likely due to lower success rates and longer development times Recruitment of trial participants is a key challenge in the area of dementia. The pipeline analysis found approximately 2,000 relevant…

Presentation at the NHS Global Health Volunteering Group Meeting: “The Value of International Volunteering and Placements to the NHS”

…productivity gains ranging from 5% to 15% if the volunteers are in the ‘doctors’ category; lower gains would be obtained for staff in lower salary bands. According to the baseline…

Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing

11 May 2018

…than with a uniform price, as well as some prices being lower. The value at which prices are currently set in a single-price system will impact on the consequences of…

How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper

18 July 2018

…is also lower for orphan drugs compared to non-orphans, as the average non-orphan patient populations were around 80 and 100 patients per 50,000 people for SMC and NICE appraised drugs…

“You Don’t Always Get What You Want”: Output Distortion and NHS Waiting Time Targets

18 December 2018

…that the policy worked to lower waiting times through a difference-in-difference approach comparing England (treatment) and Scotland (control) when the policy was first introduced. Generally, clear, measurable targets with hard…